Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 3/20 | 0.51 |
| ▸ | RXRB | P28702 | 3/20 | 0.51 |
| ▸ | RXRG | P48443 | 3/20 | 0.51 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48554 | 0.87 | AKR1B1 (0.61) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL68027 | 0.87 | LMNA (0.86) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL18427891 | 0.87 | LMNA (0.86) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL26114653 | 0.85 | AKR1B1 (0.58) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL987989 | 0.85 | AKR1B1 (0.58) | ABCC4LMNAGAATSHRPTGS1 | |
| Hydrochloric Acid SCHEMBL367129 | 0.85 | AKR1B1 (0.58) | ABCC4LMNAGAATSHRPTGS1 | |
| Hydrochloric Acid SCHEMBL11097357 | 0.85 | AKR1B1 (0.58) | ABCC4LMNAGAATSHRPTGS1 | |
| Hydrochloric Acid SCHEMBL28071881 | 0.83 | AKR1B1 (0.56) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL28103661 | 0.82 | CYP17A1 (0.56) | LMNAMMP12MMP13CA2WNT3A | |
| SCHEMBL1725021 | 0.81 | WNT3A (0.58) | ABCC4LMNAGAATSHRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2016-03-24 | — | — | US | disclosed |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2016-03-24 | — | — | US | disclosed |
| US-9238646-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators | NOVARTIS AG (CH) | 2016-01-19 | — | — | US | disclosed |
| US-9238646-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators | NOVARTIS AG (CH) | 2016-01-19 | — | — | US | disclosed |
| CN-102731379-B | N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as WNT signaling modulators | IRM LLC | 2015-05-06 | — | — | CN | disclosed |
| EP-2623493-B1 | N-(HETERO)ARYL,2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| CN-102369187-B | N- (hetero) aryl, 2- (hetero) aryl substituted acetamides as WNT signal modulators | IRM LLC | 2014-06-04 | — | — | CN | disclosed |
| US-20130310375-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2013-11-21 | — | — | US | disclosed |
| US-8546396-B2 | N-(hetero)aryl, 2-(hetero)aryl—substituted acetamides for use as Wnt signaling modulators | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| CN-102731379-A | N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators | IRM LLC | 2012-10-17 | — | — | CN | disclosed |
| CN-102369187-A | N- (hetero) aryl, 2- (hetero) aryl substituted acetamides as WNT signal modulators | IRM LLC | 2012-03-07 | — | — | CN | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
| US-7211578-B2 | Nitrogenous tetrahydropyridyl-alkyl-heterocycles with TNF activity | SANOFI-AVENTIS (FR) | 2007-05-01 | — | — | US | disclosed |
| US-20050004132-A1 | Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity | SANOFI-AVENTIS (FR) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310375-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, WNT3A, WNT3 | ABCC4 1238/4885LMNA 4347/4885GAA 3990/4885 |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | ABCC4 708/4885LMNA 3845/4885GAA 3054/4885 |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | WNT1, CTNNB1, CTNNA1 | ABCC4 708/4885LMNA 3845/4885GAA 3054/4885 |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | ABCC4 708/4885LMNA 3845/4885GAA 3054/4885 |
| US-20050004132-A1 | Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity | TNF, TNFRSF1A, NFKBIA | ABCC4 2792/4885LMNA 3216/4885GAA 1549/4885 |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, WNT3A | ABCC4 655/4885LMNA 3548/4885GAA 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.